222 related articles for article (PubMed ID: 19162045)
21. Clinical implications of aldo-keto reductase family 1 member C3 and its relationship with lipocalin 2 in cancer of the uterine cervix.
Wu CH; Ko JL; Chen SC; Lin YW; Han CP; Yang TY; Chien MH; Wang PH
Gynecol Oncol; 2014 Feb; 132(2):474-82. PubMed ID: 24316309
[TBL] [Abstract][Full Text] [Related]
22. Aldo-keto reductase 1C3 is expressed in differentiated human epidermis, affects keratinocyte differentiation, and is upregulated in atopic dermatitis.
Mantel A; Carpenter-Mendini AB; Vanbuskirk JB; De Benedetto A; Beck LA; Pentland AP
J Invest Dermatol; 2012 Apr; 132(4):1103-10. PubMed ID: 22170488
[TBL] [Abstract][Full Text] [Related]
23. AKR1C3 as a potential target for the inhibitory effect of dietary flavonoids.
Skarydová L; Zivná L; Xiong G; Maser E; Wsól V
Chem Biol Interact; 2009 Mar; 178(1-3):138-44. PubMed ID: 19007764
[TBL] [Abstract][Full Text] [Related]
24. Oxidative DNA damage induced by benz[a]anthracene dihydrodiols in the presence of dihydrodiol dehydrogenase.
Seike K; Murata M; Hirakawa K; Deyashiki Y; Kawanishi S
Chem Res Toxicol; 2004 Nov; 17(11):1445-51. PubMed ID: 15540942
[TBL] [Abstract][Full Text] [Related]
25. Prior exposure to restraint stress enhances 7,12-dimethylbenz(a)anthracene (DMBA) induced DNA damage in rats.
Muqbil I; Azmi AS; Banu N
FEBS Lett; 2006 Jul; 580(16):3995-9. PubMed ID: 16806193
[TBL] [Abstract][Full Text] [Related]
26. A novel fluorometric assay for aldo-keto reductase 1C3 predicts metabolic activation of the nitrogen mustard prodrug PR-104A in human leukaemia cells.
Jamieson SM; Gu Y; Manesh DM; El-Hoss J; Jing D; Mackenzie KL; Guise CP; Foehrenbacher A; Pullen SM; Benito J; Smaill JB; Patterson AV; Mulaw MA; Konopleva M; Bohlander SK; Lock RB; Wilson WR
Biochem Pharmacol; 2014 Mar; 88(1):36-45. PubMed ID: 24434189
[TBL] [Abstract][Full Text] [Related]
27. Regulation of a novel cell differentiation-associated gene, JWA during oxidative damage in K562 and MCF-7 cells.
Zhu T; Chen R; Li AP; Liu J; Liu QZ; Chang HC; Zhou JW
J Biomed Sci; 2005; 12(1):219-27. PubMed ID: 15864752
[TBL] [Abstract][Full Text] [Related]
28. Maternal and offspring genetic variants of AKR1C3 and the risk of childhood leukemia.
Liu CY; Hsu YH; Pan PC; Wu MT; Ho CK; Su L; Xu X; Li Y; Christiani DC;
Carcinogenesis; 2008 May; 29(5):984-90. PubMed ID: 18339682
[TBL] [Abstract][Full Text] [Related]
29. Pathophysiological roles of aldo-keto reductases (AKR1C1 and AKR1C3) in development of cisplatin resistance in human colon cancers.
Matsunaga T; Hojo A; Yamane Y; Endo S; El-Kabbani O; Hara A
Chem Biol Interact; 2013 Feb; 202(1-3):234-42. PubMed ID: 23165153
[TBL] [Abstract][Full Text] [Related]
30. Selective AKR1C3 inhibitors do not recapitulate the anti-leukaemic activities of the pan-AKR1C inhibitor medroxyprogesterone acetate.
Khanim F; Davies N; Veliça P; Hayden R; Ride J; Pararasa C; Chong MG; Gunther U; Veerapen N; Winn P; Farmer R; Trivier E; Rigoreau L; Drayson M; Bunce C
Br J Cancer; 2014 Mar; 110(6):1506-16. PubMed ID: 24569460
[TBL] [Abstract][Full Text] [Related]
31. Synthesis and structure-activity relationships for 1-(4-(piperidin-1-ylsulfonyl)phenyl)pyrrolidin-2-ones as novel non-carboxylate inhibitors of the aldo-keto reductase enzyme AKR1C3.
Heinrich DM; Flanagan JU; Jamieson SM; Silva S; Rigoreau LJ; Trivier E; Raynham T; Turnbull AP; Denny WA
Eur J Med Chem; 2013 Apr; 62():738-44. PubMed ID: 23454516
[TBL] [Abstract][Full Text] [Related]
32. Comparisons of (+/-)-benzo[a]pyrene-trans-7,8-dihydrodiol activation by human cytochrome P450 and aldo-keto reductase enzymes: effect of redox state and expression levels.
Quinn AM; Penning TM
Chem Res Toxicol; 2008 May; 21(5):1086-94. PubMed ID: 18402469
[TBL] [Abstract][Full Text] [Related]
33. Pathways of adipose tissue androgen metabolism in women: depot differences and modulation by adipogenesis.
Blouin K; Nadeau M; Mailloux J; Daris M; Lebel S; Luu-The V; Tchernof A
Am J Physiol Endocrinol Metab; 2009 Feb; 296(2):E244-55. PubMed ID: 18984855
[TBL] [Abstract][Full Text] [Related]
34. Differentiation in chronic myelogenous leukemia cell K562 by spongean sesterterpene.
Aoki S; Higuchi K; Isozumi N; Matsui K; Miyamoto Y; Itoh N; Tanaka K; Kobayashi M
Biochem Biophys Res Commun; 2001 Mar; 282(2):426-31. PubMed ID: 11401476
[TBL] [Abstract][Full Text] [Related]
35. Hydroxytriazole derivatives as potent and selective aldo-keto reductase 1C3 (AKR1C3) inhibitors discovered by bioisosteric scaffold hopping approach.
Pippione AC; Giraudo A; Bonanni D; Carnovale IM; Marini E; Cena C; Costale A; Zonari D; Pors K; Sadiq M; Boschi D; Oliaro-Bosso S; Lolli ML
Eur J Med Chem; 2017 Oct; 139():936-946. PubMed ID: 28881288
[TBL] [Abstract][Full Text] [Related]
36. Aldo-keto reductase family 1 member C3 (AKR1C3) is expressed in adenocarcinoma and squamous cell carcinoma but not small cell carcinoma.
Miller VL; Lin HK; Murugan P; Fan M; Penning TM; Brame LS; Yang Q; Fung KM
Int J Clin Exp Pathol; 2012; 5(4):278-89. PubMed ID: 22670171
[TBL] [Abstract][Full Text] [Related]
37. Nonsteroidal anti-inflammatory drugs and their analogues as inhibitors of aldo-keto reductase AKR1C3: new lead compounds for the development of anticancer agents.
Gobec S; Brozic P; Rizner TL
Bioorg Med Chem Lett; 2005 Dec; 15(23):5170-5. PubMed ID: 16183274
[TBL] [Abstract][Full Text] [Related]
38. Crystal structures of three classes of non-steroidal anti-inflammatory drugs in complex with aldo-keto reductase 1C3.
Flanagan JU; Yosaatmadja Y; Teague RM; Chai MZ; Turnbull AP; Squire CJ
PLoS One; 2012; 7(8):e43965. PubMed ID: 22937138
[TBL] [Abstract][Full Text] [Related]
39. Selective inhibition of human type-5 17β-hydroxysteroid dehydrogenase (AKR1C3) by baccharin, a component of Brazilian propolis.
Endo S; Matsunaga T; Kanamori A; Otsuji Y; Nagai H; Sundaram K; El-Kabbani O; Toyooka N; Ohta S; Hara A
J Nat Prod; 2012 Apr; 75(4):716-21. PubMed ID: 22506594
[TBL] [Abstract][Full Text] [Related]
40. p210(Bcr-Abl) desensitizes Cdc42 GTPase signaling for SDF-1alpha-directed migration in chronic myeloid leukemia cells.
Chang YC; Tien SC; Tien HF; Zhang H; Bokoch GM; Chang ZF
Oncogene; 2009 Nov; 28(46):4105-15. PubMed ID: 19718053
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
